Literature DB >> 16432141

Inclusion-body myositis: clinical, diagnostic, and pathologic aspects.

W King Engel1, Valerie Askanas.   

Abstract

The diagnostic aspects of sporadic inclusion-body myositis (s-IBM), and a few comments on our own approach to its treatment, are presented to foster the goals of this symposium, which was organized to provoke new ideas concerning the cause and treatment of this currently unsolvable disease. s-IBM is the most common, progressive, debilitating muscle disease beginning in persons over age 50 years, and it is more common in men. Diagnostic parameters reviewed are clinical, muscle-biopsy histochemistry, electrophysiologic and CSF evaluations. Overall, the degenerative phenomena in s-IBM muscle fibers seem to be the major cause of the progressive, unstoppable weakness, rather than the lymphocytic inflammation. Available treatments are of only slight, temporary benefit for only some s-IBM patients, indicating a desperate need for definitive therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432141     DOI: 10.1212/01.wnl.0000192260.33106.bb

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

1.  Increased BACE1 mRNA and noncoding BACE1-antisense transcript in sporadic inclusion-body myositis muscle fibers--possibly caused by endoplasmic reticulum stress.

Authors:  Anna Nogalska; W King Engel; Valerie Askanas
Journal:  Neurosci Lett       Date:  2010-03-15       Impact factor: 3.046

2.  A case of inclusion body myositis responsive to prednisolone therapy.

Authors:  Rahul Kalla; Majella Soumakiyan; Stephen Tuck
Journal:  Clin Rheumatol       Date:  2008-12-06       Impact factor: 2.980

3.  Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis.

Authors:  Kenneth C Parker; Sek Won Kong; Ronan J Walsh; Mohammad Salajegheh; Behzad Moghadaszadeh; Anthony A Amato; Remedios Nazareno; Yin Yin Lin; Bryan Krastins; David A Sarracino; Alan H Beggs; Jack L Pinkus; Steven A Greenberg
Journal:  Muscle Nerve       Date:  2009-06       Impact factor: 3.217

4.  Neuromuscular ultrasound in the evaluation of inclusion body myositis.

Authors:  Quang Vu; Michael Cartwright
Journal:  BMJ Case Rep       Date:  2016-10-20

5.  Activation of the Unfolded Protein Response in Sporadic Inclusion-Body Myositis but Not in Hereditary GNE Inclusion-Body Myopathy.

Authors:  Anna Nogalska; Carla D'Agostino; W King Engel; Mafalda Cacciottolo; Shinichi Asada; Kazutoshi Mori; Valerie Askanas
Journal:  J Neuropathol Exp Neurol       Date:  2015-06       Impact factor: 3.685

Review 6.  Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention.

Authors:  James P Solomon; Lesley J Page; William E Balch; Jeffery W Kelly
Journal:  Crit Rev Biochem Mol Biol       Date:  2012-02-24       Impact factor: 8.250

7.  Neuromuscular Mimics of Entrapment Neuropathies of Upper Extremities.

Authors:  James M Gilchrist; Sudeepta Dandapat
Journal:  Hand (N Y)       Date:  2020-02-05

8.  Formation of gelsolin amyloid fibrils in the rough endoplasmic reticulum of skeletal muscle in the gelsolin mouse model of inclusion body myositis: comparative analysis to human sporadic inclusion body myositis.

Authors:  Sergei I Bannykh; William E Balch; Jeffery W Kelly; Lesley J Page; G Diane Shelton
Journal:  Ultrastruct Pathol       Date:  2013-10       Impact factor: 1.094

9.  Vacuolar myopathy in a dog resembling human sporadic inclusion body myositis.

Authors:  Jason King; Richard A LeCouteur; Monica Aleman; D Colette Williams; Peter F Moore; Ling T Guo; Andrew P Mizisin; G Diane Shelton
Journal:  Acta Neuropathol       Date:  2009-08-29       Impact factor: 17.088

10.  How citation distortions create unfounded authority: analysis of a citation network.

Authors:  Steven A Greenberg
Journal:  BMJ       Date:  2009-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.